[Market Focus] AJU IB Investment Soars 30% on Hopes for Investment Returns

The stock price of AJU IB Investment, a venture capital (VC) firm, surged on heightened expectations for global bio investment returns.

As of 10:03 a.m. on February 27, AJU IB Investment was trading at 5,810 won, up 1,340 won (29.98%) from the previous day.

According to foreign media reports the previous day, global pharmaceutical company Gilead has agreed to acquire Axcella Therapeutics, a bio company invested in by Solasta Ventures, for 7.8 billion dollars (about 10 trillion won). Axcella Therapeutics is a company invested in by Solasta Ventures, the U.S. subsidiary of AJU IB Investment.

AJU IB Investment has been divesting from Axcella Therapeutics since its listing on the NASDAQ in 2023 and into last year. It is known that the company still holds a significant portion of shares. AJU IB Investment expects an investment multiple of up to 9 times its original principal.

This content was produced with the assistance of AI translation services.